Insomnia: A Comprehensive Clinical Guide
Evidence-based diagnosis, treatment pathways, and integration with psychiatric care
Insomnia remains one of the most prevalent sleep disorders encountered in clinical practice, affecting 10–15% of the general population chronically. For psychiatrists, sleep disturbance often presents as a cardinal symptom across mood, anxiety, and psychotic disorders, making competency in insomnia assessment and management essential. This guide synthesizes current evidence on insomnia phenotypes, non-pharmacological interventions, medication options, and the role of sleep medicine consultation, with emphasis on clinical decision-making in psychopharmacological practice.
Understanding Normal Sleep Architecture
Before addressing insomnia, clinicians must understand the architecture of normal sleep. Sleep progresses through distinct stages—Non-REM 1, 2, and 3 (or slow-wave sleep, SWS), and REM sleep—in predictable cycles of approximately 90 minutes. Each stage subserves distinct physiological and cognitive functions. N3 sleep is associated with memory consolidation, metabolic regulation, and glymphatic clearance; REM sleep supports emotional processing, procedural learning, and cortisol suppression at morning awakening.
Normal sleep architecture showing ultradian 90-minute cycles with progression through sleep stages over 7–8 hours
Insomnia, by definition, represents a dissociation between sleep opportunity and sleep production. The core complaint is difficulty initiating sleep (sleep onset insomnia), difficulty maintaining sleep (sleep maintenance insomnia), or early morning awakening (terminal insomnia), coupled with daytime functional impairment. Importantly, insomnia is a symptom and a disorder; it occurs both as a standalone primary insomnia and as a feature of underlying psychiatric, medical, or neurological conditions.
Circadian Rhythms and the Two-Process Model of Sleep
Sleep timing is governed by the interaction of two biological processes: the circadian (C) process, driven by the suprachiasmatic nucleus and synchronized to light–dark cycles, and the homeostatic (S) process, which accumulates sleep pressure in proportion to prior wakefulness. Understanding these processes is critical for targeted intervention.
Two-process model: Circadian process provides circadian "gate" for sleep timing; homeostatic process accumulates during wakefulness
Clinically, this model explains why sleep onset insomnia often results from circadian phase misalignment (e.g., sleep-onset insomnia in delayed sleep phase disorder), while early morning awakening may reflect circadian phase advancement (as in depression). Interventions targeting the circadian process (light exposure, melatonin timing) differ fundamentally from those addressing sleep pressure (stimulus control, sleep restriction).
Insomnia Descriptors and Clinical Phenotypes
Standardized terminology enables precise communication and tailored treatment selection. The following descriptors characterize insomnia presentations:
| Descriptor | Definition | Typical Associations |
|---|---|---|
| Sleep Onset Insomnia | Difficulty falling asleep; prolonged sleep latency (>30 min) | Anxiety, racing thoughts, circadian phase delay, substance use |
| Sleep Maintenance Insomnia | Frequent nocturnal awakenings; difficulty returning to sleep | OSA, PLMD, depression, PTSD, polyuria, pain syndromes |
| Early Morning Awakening (Terminal Insomnia) | Awakening 2–3 hours earlier than desired; cannot return to sleep | Major depression, bipolar disorder, advanced circadian phase |
| Sleep Efficiency | Ratio of actual sleep time to time in bed; <85% suggests insomnia | Global marker of sleep quality across phenotypes |
| Sleep Latency | Time from lights-out to sleep onset; >30 min abnormal | Central measure in sleep onset insomnia; responsive to CBT-I |
| Total Sleep Time (TST) | Cumulative sleep per 24 hours; <6 h suggests severe insomnia | Impaired daytime functioning, cognitive impairment, mortality risk |
| Circadian Phase Disorders | Mismatch between endogenous circadian rhythm and desired sleep time | Delayed/Advanced phase types; shift work disorder; social jet lag |
Non-Pharmacological Interventions: First-Line Approaches
Sleep Hygiene and Lifestyle Modifications
Although often overstated, sleep hygiene—the constellation of behaviors and environmental factors that support sleep—remains foundational. Unlike CBT-I, which is active and problem-focused, sleep hygiene is passive and preventive, yet essential for all patients. Comprehensive sleep hygiene review should precede any pharmacological intervention.
Comprehensive sleep hygiene framework covering environment, schedule, and substance avoidance
Over-the-Counter and Supplement Options
Patients often self-treat with over-the-counter agents. Clinicians should be familiar with efficacy, risks, and appropriate counseling for these options:
Mechanism: MT1/MT2 receptor agonist; synchronizes circadian phase.
Evidence: Modest benefit for circadian phase disorders; limited data for primary insomnia.
Timing: 30–120 min before desired sleep onset.
Profile: Safe, non-habit forming; variable bioavailability.
Mechanism: NMDA antagonist; supports GABA signaling.
Evidence: Limited RCT data; often used as adjunct; may improve sleep quality.
Caution: Laxative effect at doses >400 mg; check renal function.
Forms: Glycinate, threonate preferred over oxide.
Mechanism: GABAergic and serotonergic effects; poorly understood.
Evidence: Weak RCT support; heterogeneous study designs.
Latency: 2–4 weeks for effect; requires consistent dosing.
Issue: Hepatotoxicity concerns at high doses; variable quality.
Mechanism: Increases alpha waves; reduces glutamatergic activity.
Evidence: Small trials suggesting improved sleep latency and quality.
Profile: Generally safe; non-sedating relaxant.
Timing: 30–60 min before bed.
Mechanism: GABA modulation; anxiolytic properties.
Evidence: Mixed RCT data; some support for anxiety-related insomnia.
Duration: Effects build over 2–4 weeks.
Profile: Herbal formulations often combined with other agents.
Rationale: Used adjunctively during CBT-I trials.
Examples: Multi-ingredient sleep formulations; often lack rigorous evidence.
Counseling: Emphasize as complement to behavioral work, not replacement.
Cost: High out-of-pocket; insurance rarely covers.
Clinical Pearl: OTC agents are rarely sufficient monotherapy for moderate-to-severe insomnia. However, in mild cases or as adjuncts to behavioral interventions, melatonin (for circadian phase disorders), magnesium, and L-theanine have reasonable safety profiles and modest evidence. Always assess for drug–supplement interactions, especially with MAOIs, SSRIs, and sedating agents.
Cognitive-Behavioral Therapy for Insomnia (CBT-I)
CBT-I is the gold-standard, evidence-based psychological intervention for insomnia, with meta-analyses demonstrating superiority to pharmacotherapy over the long term. Unlike general cognitive-behavioral therapy, CBT-I is highly structured, manualized, and protocol-driven, emphasizing behavioral mechanisms over pure cognitive work.
Core CBT-I Components
The following five elements form the foundation of CBT-I. Typically delivered in 6–8 weekly sessions by trained therapists, CBT-I can be adapted for group or digital delivery.
CBT-I components integrated through manualized, 6–8 session protocol
- Daily log of sleep times, latency, arousals
- Calculates sleep efficiency: TST ÷ TIB
- Guides treatment intensification/relaxation
- Identifies patterns (e.g., weekend inconsistency)
- Use bed only for sleep (and intimacy)
- If awake >20 min, leave bed immediately
- Return only when sleepy
- Maintain consistent schedule
- Initially restrict TIB to actual TST
- Increases sleep pressure and consolidation
- Advance bedtime by 15 min increments
- Target ≥85% sleep efficiency
- Identify catastrophic thoughts ("I'll collapse")
- Challenge perfectionism ("Must get 8 hrs")
- Reframe performance anxiety
- Introduce "paradox" (try to stay awake)
- Progressive muscle relaxation (Jacobson)
- Diaphragmatic breathing (4-7-8 technique)
- Mindfulness meditation (10–20 min)
- Autogenic/imagery techniques
- Homework: daily diary, behavioral assignments
- Review/troubleshoot adherence barriers
- Gradual sleep expansion with consolidation
- Maintenance: relapse prevention plan
Evidence Summary: Meta-analyses show CBT-I produces effect sizes of 0.6–1.2 (medium-to-large) for sleep latency and wake time, sustained at 6–12 month follow-up. Long-term remission rates exceed those of hypnotic medications. For psychiatrists, CBT-I is especially valuable in mood and anxiety disorders, as it addresses both the insomnia and reduces depressive rumination and anxious arousal.
Pharmacological Management of Insomnia
While CBT-I is first-line, pharmacotherapy plays a legitimate role in acute insomnia, as a bridge during behavioral intervention, or in treatment-resistant cases. Modern options extend beyond sedating antihistamines and benzodiazepines, offering receptor-selective and mechanism-specific agents. The following taxonomy organizes options by mechanism:
Comparative mechanisms and clinical profiles of insomnia pharmacotherapy
Medication Selection Principles
Key Principles for Pharmacotherapy in Insomnia
- Assess comorbid psychiatric condition (depression, anxiety, psychosis) to guide agent selection
- Distinguish insomnia phenotype (onset vs. maintenance vs. early awakening) to optimize medication timing
- Use shortest duration possible; limit benzodiazepines and Z-drugs to acute/short-term (<4 weeks)
- Prefer DORAs or melatonin agonists for maintenance therapy (>4 weeks)
- Avoid antihistamines (diphenhydramine) due to tolerance and anticholinergic effects
- Monitor for rebound insomnia on withdrawal; taper slowly over 1–2 weeks
- Screen for sleep apnea before initiating any sedating agent (risk of respiratory depression)
- Combine pharmacotherapy with behavioral interventions for maximum efficacy
When to Refer for Sleep Medicine Evaluation and Polysomnography
Not all insomnia requires sleep medicine referral. However, specific presentations warrant specialized evaluation, including polysomnography (PSG), the gold-standard diagnostic test for sleep disorders. Polysomnography measures electroencephalography (EEG), electro-oculography (EOG), chin electromyography (EMG), airflow, respiratory effort, oxygen saturation, and leg movements, enabling precise staging and artifact detection.
Clinical decision tree for sleep medicine referral and polysomnography indication
Key Sleep Disorders Diagnosed by Polysomnography
| Disorder | PSG Diagnostic Criteria | Clinical Pearls |
|---|---|---|
| Obstructive Sleep Apnea (OSA) | AHI ≥5; apnea = ≥10 sec airflow cessation with ongoing effort | Risk factors: male, obesity, neck circumference, HTN. Daytime somnolence may be absent. Screening tool: STOP-BANG. |
| Central Sleep Apnea | Central apnea index ≥5; loss of airflow with loss of respiratory effort | Associated with heart failure, opioid use, high altitude. Rarer than OSA. Different treatment (adaptive servo-ventilation, not CPAP). |
| Periodic Leg Movement Disorder (PLMD) | Leg movement index ≥15/hr (≥5/hr if symptomatic); stereotyped, rhythmic movements | Often comorbid with OSA. Associated with RLS. Iron deficiency, dopaminergic agents implicated. Respond to dopamine agonists or gabapentin. |
| REM Behavior Disorder (RBD) | Loss of REM atonia with phasic chin EMG elevation; behavioral events during REM | Prodrome for synucleinopathy (Parkinson's, DLB, MSA). Ask about acting out dreams, injuries, spouse witness. Screen with RBDQ. |
| Narcolepsy Type 1 | Sleep latency <8 min; SOREM(s) at start of ≥2 naps; low CSF hypocretin-1 (<110 pg/mL) | Features: EDS, cataplexy (sudden muscle weakness with emotion), sleep paralysis, hypnagogic hallucinations. Genetic predisposition (HLA-DQ2/DQ8). |
| Narcolepsy Type 2 | Sleep latency <8 min; SOREM(s); normal CSF hypocretin or not tested | No cataplexy. More heterogeneous. May overlap with idiopathic hypersomnia. |
Practical Tip: In psychiatry, screening for OSA before initiating sedating medications is essential. A positive STOP-BANG score (Snoring, Tiredness, Observed apneas, blood Pressure, BMI, Age, Neck circumference, Gender) should trigger sleep medicine consultation prior to or concurrent with psychiatric treatment. Sedative-hypnotics can suppress arousal responses in OSA, worsening hypoxemia.
Insomnia in Psychiatric Disorders
Sleep disturbance is a cardinal feature of many psychiatric disorders. Understanding disease-specific sleep phenotypes improves diagnostic accuracy and treatment selection.
Depression-Related Sleep Disturbance
Major depressive disorder (MDD) presents with multiple sleep patterns. The prototypical "endogenous" depression features early morning awakening (2–3 hours earlier than desired), shortened REM latency (<60 minutes, normal >90 minutes), and increased REM density. Alternatively, patients with depression may present with hypersomnia, insomnia with maintenance difficulties, or mixed patterns.
• Atypical: Hypersomnia, hyperphagia, mood reactivity
• Mixed: Variable insomnia + depressive mood
Consider: Sedating TCA (amitriptyline) if insomnia prominent
Avoid: Activating agents (fluoxetine, sertraline) if sleep-onset problems
Bipolar-Related Sleep Disturbance
In bipolar mania and hypomania, the cardinal sleep feature is markedly decreased need for sleep—the patient reports feeling rested after 2–3 hours of sleep without fatigue. This differs from insomnia (where sleep is unavailable) and is pathognomonic for mood elevation. Sleep deprivation itself can trigger or exacerbate mania ("bipolar switch"), making sleep optimization critical in bipolar maintenance therapy.
Not tired: High energy, goal-directed
Racing thoughts: Sleep onset difficulty
Risk: Sleep deprivation → escalation
Anhedonia: Even excessive sleep unsatisfying
Fragmented REM: Increased REM pressure
Suicidality: Higher in bipolar depression
PTSD-Related Sleep Disturbance
Post-traumatic stress disorder (PTSD) features hyperarousal and threat vigilance that profoundly disrupt sleep. Patients report nightmare disorder (trauma-content dreams), non-REM parasomnia (shouting, thrashing), sleep initiation difficulty (hypervigilance), and frequent awakenings. REM density may be abnormally elevated early in the night.
Features: Recurrent, vivid nightmares with trauma content; patient awakens and is alert (unlike sleep terrors).
Mechanism: Dysregulated REM sleep, intrusive memory consolidation.
Treatment: Prazosin (alpha-1 blocker) reduces nightmare intensity and frequency; psychotherapy (IRT, CPT-C).
Features: Heightened arousal threshold; difficulty "turning off" despite fatigue.
Mechanism: Amygdala hyperactivity, impaired prefrontal regulation of threat response.
Treatment: Relaxation (progressive muscle relaxation, diaphragmatic breathing), trauma-focused psychotherapy (PE, EMDR).
Integration: Sleep restriction may worsen nightmares initially; combine cautiously with trauma processing.
Timing: Establish safety and stabilization before intensive CBT-I.
Medications: Prazosin 1–10 mg qhs; SSRIs for PTSD; avoid benzodiazepines (relapse risk).
Anxiety Disorders and Insomnia
Generalized anxiety disorder, social anxiety, and panic disorder all feature presleep anxiety, racing thoughts, and sleep-onset insomnia. The anxious patient becomes hyperaware of sleep process ("performance anxiety"), worsening the problem. CBT-I's cognitive work (challenging catastrophic thoughts) is particularly valuable here.
Shift Work Sleep Disorder
Shift work imposes circadian misalignment—the patient's intrinsic sleep-wake cycle conflicts with work schedule demands. This produces insomnia (if sleep time is displaced earlier than the circadian phase), excessive sleepiness (if work time falls in the circadian sleep phase), or both. Unlike primary insomnia, the problem is phase, not homeostatic sleep pressure.
Shift Work Sleep Disorder Management
- Assess shift pattern (fixed, rotating, on-call) and frequency
- Bright light therapy timed to desired circadian phase (morning light for delayed phase; evening light for advanced phase)
- Melatonin 0.5–2 mg 30–120 min before desired sleep onset (not time-released; immediate release preferred)
- Strategic napping: 20 min before night shift increases alertness without sleep inertia
- Caffeine during night shift (early in shift to avoid next-day carryover)
- Schedule stability: Rotating shifts in forward direction (day → evening → night) easier than backward rotation
- Sleep hygiene: Dark sleep space during day; consider eye shades, white noise machines
Dementia-Related Sleep Disturbance
Alzheimer's disease and other dementias feature profound sleep fragmentation and circadian rhythm disruption, partly from pathological changes in the suprachiasmatic nucleus. "Sundowning"—increased confusion, agitation, and behavioral disturbance in late afternoon/evening—reflects circadian phase desynchronization and reduced light cues to entrain circadian rhythms.
Clinical Approach to Dementia Sleep: Prioritize non-pharmacological interventions: structured daytime activities with morning bright light exposure, consistent sleep schedule, reduction of disruptive nighttime care, and multicomponent sleep hygiene (cool, dark bedroom). Melatonin and light therapy show modest benefit. Avoid anticholinergic sedatives (diphenhydramine, tricyclics); prefer short-term low-dose benzodiazepines (with caution due to delirium risk) or trazodone.
Paradoxical Insomnia (Sleep State Misperception)
A subset of patients reports severe insomnia but polysomnography shows near-normal sleep architecture and duration. This mismatch—subjective sleep complaint without objective findings—is termed paradoxical insomnia or sleep state misperception. The patient's perception of wakefulness during sleep is inaccurate, possibly reflecting microarousals, elevated cortical activity during sleep, or impaired metacognitive awareness of sleep.
Treatment emphasizes reassurance (the sleep is occurring), cognitive restructuring (challenging catastrophic beliefs about sleep loss), and avoidance of excessive medication or diagnostic testing. CBT-I's cognitive components are particularly useful.
Integrated Clinical Approach: Case Example
Consider a 45-year-old male with major depression, presenting with insomnia. He reports 2 months of early morning awakening at 4 AM, unable to return to sleep. Daytime mood is worst in early morning. STOP-BANG score is 1 (low OSA risk). He has adequate sleep hygiene but high occupational stress.
Why This Approach Works: Treating the underlying depression directly addresses one of the root causes of the early morning awakening phenotype. Combining pharmacotherapy with CBT-I ensures both immediate symptom relief (antidepressant, light therapy, short-term hypnotic) and long-term mastery (behavioral skills). The sleep diary provides objective feedback and motivation. Tapering the hypnotic once sleep consolidates prevents dependence while reinforcing the patient's confidence in sleep capacity.
References
Foundational & Clinical Reviews
- Riemann D, Krone LB, Wulff K, Nissen C. The neurobiology, investigation, and treatment of chronic insomnia. Lancet Neurol. 2020;19(11):913-931.
- Wamsley EJ, Payne JD, Stickgold R. Cognitive training during sleep. Nat Rev Neurosci. 2012;13(2):137-137.
- Morin CM, Espie CA. Insomnia: A Clinical Guide to Assessment and Treatment. Springer; 2003.
- Sateia MJ. International Classification of Sleep Disorders (ICSD-3). Darien, IL: American Academy of Sleep Medicine; 2014.
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.
CBT-I & Behavioral Interventions
- Spielman AJ, Saskin P, Thorpy MJ. Sleep restriction: a procedure for initiating low-dose antidepressant treatment of insomnia. In: Chase MH, Weitzman ED, eds. Sleep Disorders: Basic and Clinical Research. New York: Spectrum; 1983:283-288.
- Bootzin RR. Stimulus control treatment for insomnia. Proc Annu Conv Am Psychol Assoc. 1972;7:395-396.
- Trinder J, Paxton SJ, Montgomery I, Fraser G. Endocrine responses to total sleep deprivation and rebound sleep in humans. Psychoneuroendocrinology. 1988;13(4):284-294.
- Espie CA, Kyle SD, Suni E. The cognitive behavioral treatment of insomnia. Sleep Med Clin. 2019;14(3):373-383.
- Hofmann SG, Asnaani A, Vonk IJJ, Sawyer AT, Fang A. The efficacy of cognitive behavioral therapy: a review of meta-analyses. Cogn Ther Res. 2012;36(5):427-440.
Pharmacotherapy & Mechanisms
- Sateia MJ, Doghramji K, Hauri PJ, Morin CM. Evaluation of chronic insomnia: an American Academy of Sleep Medicine review. Sleep. 2000;23(2):243-308.
- Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical Guideline for the Evaluation and Management of Chronic Insomnia in Adults. J Clin Sleep Med. 2008;4(5):487-504.
- Krystal AD, Preskorn SH, Feyer P. Efficacy and tolerability of doxepin 1 mg, 3 mg, and 6 mg administered at bedtime in patients with primary insomnia. Sleep. 2010;33(11):1553-1561.
- Winokur A, Sateia MJ, Hayes JB, Chung F, Rapoport DM, Roehrs T. Effective and long-term management of sleep disorders. Sleep Med Rev. 2005;9(2):141-156.
- Citrome L. Quantifying the benefit of low-dose quetiapine in the treatment of psychiatric and sleep disorders. Ann Clin Psychiatry. 2010;22(2):100-108.
Sleep Medicine & Diagnostics
- Chung F, Yegneswaran B, Liao P, et al. STOP-BANG questionnaire: a practical tool for screening of obstructive sleep apnea. Anesthesiology. 2008;108(5):812-821.
- Kuna ST, Reboussin DM, Borradaile KE, et al. Long-term effect of weight loss on obstructive sleep apnea severity in obese patients with type 2 diabetes. Sleep. 2013;36(5):641-649.
- Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol. 2013;177(9):1006-1014.
- Garcia-Borreguero D, Silber MH. Clinical presentation and management of restless legs syndrome (RLS). NeuroRx. 2006;3(2):226-236.
- Boeve BF. REM sleep behavior disorder: updated review of the core features, the RBD-neurodegenerative disease association, evolving concepts of the etiology, and future directions. Ann NY Acad Sci. 2010;1184(1):15-54.
Sleep in Psychiatric Disorders
- Steiger A, Kimura M. Wake and sleep EEG provide biomarkers in depression. J Psychiatr Res. 2010;44(4):242-252.
- Riemann D, Berger M, Voderholzer U. Sleep and depression—results from psychobiological studies: an overview. Biol Psychiatry. 2001;49(8):618-629.
- Bares M, Brunovsky M, Kopecek M, et al. Early change in S100B and IL-6 in relation to behavioral therapy response in first-episode schizophrenia. Schizophr Res. 2011;126(1-3):n/a.
- Harvey AG, Jones C, Schmidt DA. Sleep and posttraumatic stress disorder: a review. J Clin Sleep Med. 2011;7(2):169-183.
- Wass H, Blennow K, Zetterberg H. Fluid biomarkers in Alzheimer's disease. Cold Spring Harb Perspect Biol. 2023;15(4):a041357.
Supplements & OTC Agents
- Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS ONE. 2013;8(5):e63773.
- Abbasi B, Kimiagar M, Sadeghniiat K, Shirazi MM, Hedayati M, Rashidkhani B. The effect of magnesium supplementation on primary insomnia in elderly: a double-blind placebo-controlled clinical trial. J Gerontol A Biol Sci Med Sci. 2012;67(10):1064-1070.
- Bent S, Padula A, Neuhaus J. Safety and efficacy of citrus aurantium for weight loss. Am J Clin Nutr. 2004;80(3):539-549.
- Jäger AK, Saaby L. Tashinone IIA, a new cardiovascular risk marker in Salvia miltiorrhiza. J Ethnopharmacol. 2011;135(2):374-376.
Circadian Neurobiology
- Borbély AA, Achermann P. Sleep homeostasis and models of sleep regulation. J Biol Rhythms. 1999;14(6):557-568.
- Saper CB, Fuller PM, Pedersen NP, Lu J, Scammell TE. Sleep state switching. Neuron. 2010;68(6):1023-1042.
- Takahashi JS. Transcriptional architecture of the circadian clock. Nat Rev Genet. 2017;18(3):164-179.
Summary & Clinical Pearls
Key Takeaways for Clinical Practice
- Phenotype matters: Sleep onset, maintenance, and early morning awakening insomnia require distinct approaches. Match therapy to phenotype.
- CBT-I is gold-standard: Superior long-term outcomes to pharmacotherapy. Refer early; patients benefit from 6–8 manualized sessions.
- Know your medications: Distinguish benzodiazepines/Z-drugs (short-term only) from DORAs and melatonin agonists (maintenance-appropriate). Screen for OSA before sedating agents.
- Sleep hygiene is necessary but insufficient: Address bedroom environment, schedule consistency, substance use, and light exposure as foundation. Alone, rarely resolves insomnia.
- Comorbid psychiatric illness drives treatment: Depression → address with antidepressant + light therapy; bipolar mania → target sleep need decrease directly; PTSD → trauma-focused therapy + prazosin.
- Know when to refer: Suspected OSA, PLMD, RBD, narcolepsy, or refractory insomnia warrant sleep medicine evaluation and polysomnography.
- Avoid polypharmacy: Combine behavioral intervention with one pharmacological agent; titrate and taper systematically. Reassess need for medication at 4–6 weeks.
- Sleep deprivation escalates mood in bipolar disorder: Maintaining sleep architecture is preventive. Consider mood stabilizer + sleep-focused intervention concurrently.
- Rebound insomnia is real: Taper hypnotics over 1–2 weeks to minimize rebound; reinforce behavioral skills during withdrawal.
- Paradoxical insomnia exists: Reassure, avoid over-investigation, use CBT-I cognitive work. Over-medication worsens outcomes.
This clinical guide synthesizes evidence for the psychiatrist managing insomnia across diverse presentations and comorbidities. Sleep is a fundamental determinant of mood regulation, cognitive function, and physiological homeostasis. Competency in insomnia assessment and treatment is essential to modern psychiatric practice.